Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Ono’s Cancer Cachexia Drug to Finally Come Up for PAFSC Review on Dec. 11
Ono Pharmaceutical’s cancer cachexia treatment anamorelin will finally be put on the table for discussion at a key advisory committee meeting on December 11. The health ministry says it is now ready to answer questions raised by panel members, who…
To read the full story
Related Article
- PAFSC Likely to Skip Review of Ono’s Cancer Cachexia Drug Yet Again
November 20, 2020
- Lilly’s Galcanezumab Up for PAFSC Review for Migraine Prevention on Dec. 2
November 19, 2020
REGULATORY
- Pharma Seeks Inflation-Liked Price Hikes, Freeze on Patent-Period Cuts for 2027 Revision
August 27, 2026
- Kisunla Braced for NHI Price Cut after CEA; Leqembi Method to Apply
August 27, 2026
- Xcopri, Leqembi SC Now in Line for Japan Approval with Panel Backing
August 27, 2026
- MHLW Seeks Record 36.6 Trillion Yen for FY2027, Puts AI in Focus
August 27, 2026
- Generic Re-Pricing Relief Reaches Just 1 in 10 Unprofitable Products: JGA
August 27, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…